Atlas Trials

A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Clinical trial NCT07753369 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07753369
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status
NOT_YET_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Small Lymphocytic LympphoRelapsed/Refractory Chronic Lymphocytic Leukemia
Start date
2026-08-01
Primary completion
2030-12-01
Enrollment
128

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.